RecruitingNCT06647134
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Sponsor
M.D. Anderson Cancer Center
Enrollment
20 participants
Start Date
Sep 11, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- The criteria are:
- Patients aged 18 years and above
- English (conversational level) speaking, with the ability to give informed consent
- Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy
Exclusion Criteria2
- Acutely life-threatening or worsening cancer
- Hearing impairment functionally limiting participation in verbal interview
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06647134
Related Trials
Synovial Fluid Bank From Arthritic Patients
NCT005123431 location
Natural History and Development of Spondyloarthritis
NCT014226941 location
Studies of the Natural History of Rheumatic Diseases
NCT000244791 location
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NCT0696057759 locations
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
NCT065769215 locations